The earnings call highlighted significant progress in pipeline expansion and positive clinical trial outcomes, paired with successful cost management strategies. However, financial challenges persist, as evidenced by the net loss and dependency on royalty revenues. While the highlights suggest optimism for future growth, the financial and operational challenges maintain a balanced outlook.

Company Guidance

During the BioLineRx Second Quarter 2025 Financial Results Conference Call, the company provided several key metrics and guidance updates. They reported $1.7 million in APHEXDA sales, resulting in $0.3 million of royalty revenues. BioLineRx is well-financed, with cash and equivalents of $28.2 million, sufficient to fund operations into the first half of 2027, extending their previous guidance. Research and development expenses were $2.3 million, and the net loss for the quarter was $3.9 million. The company is actively pursuing the acquisition of new early-stage assets in oncology and rare diseases, with a target to execute a transaction by the end of the year. BioLineRx also highlighted promising clinical data and ongoing trials, including a Phase IIb PDAC trial and two Phase I trials for sickle cell disease, which could potentially yield long-term milestones and royalties.

Progress in Pipeline Expansion

BioLineRx is making excellent progress in evaluating promising early-stage assets in oncology and rare diseases to support pipeline expansion, targeting the execution of a transaction this year.

Collaborative Study Success

The PDAC trial in collaboration with Columbia University showed a partial response rate of 64%, significantly higher than the historical rate of 23%. Additionally, 91% of patients exhibited disease control compared to the historical rate of 48%.

Positive ASCO Presentation

New data from a pancreatic cancer study was presented at ASCO, showing a significant increase in CD8-positive T cell density in tumors, suggesting potential to overcome tumor immunosuppressive mechanisms.

Extended Cash Runway

BioLineRx ended Q2 2025 with $28.2 million in cash and equivalents, extending their cash runway into the first half of 2027, compared to previous guidance through the second half of 2026.

Significant Reduction in Operating Expenses

The company reduced its operating cash burn by more than 70% after restructuring and shutting down U.S. operations, transforming into a leaner organization.

Bioline RX Ltd Sponsored ADR (BLRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BLRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Dec 01, 2025	2025 (Q3)	-0.36 / -	0	―	―	―
Aug 14, 2025	2025 (Q2)	-0.35 / 0.00	0	―	―
May 27, 2025	2025 (Q1)	- / 0.00	0	―	―
Mar 31, 2025	2024 (Q4)	-0.95 / 0.00	0	―	―
Nov 25, 2024	2024 (Q3)	-1.74 / 0.00	-12	―	―
Aug 15, 2024	2024 (Q2)	-3.02 / 0.00	-12	―	―
May 28, 2024	2024 (Q1)	-11.66 / 0.00	-6	―	―
Mar 26, 2024	2023 (Q4)	-8.84 / -7.64	-3.618	-111.11% (-4.02)	―
Nov 20, 2023	2023 (Q3)	-8.44 / -12.00	-6	-100.00% (-6.00)	―
Aug 30, 2023	2023 (Q2)	-6.83 / -12.00	-6	-100.00% (-6.00)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BLRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$3.94	$3.77	-4.31%
May 27, 2025	$3.66	$3.68	+0.55%
Mar 31, 2025	$3.05	$2.96	-2.95%
Nov 25, 2024	$11.12	$10.87	-2.25%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Bioline RX Ltd Sponsored ADR (BLRX) report earnings?

Bioline RX Ltd Sponsored ADR (BLRX) is schdueled to report earning on Dec 01, 2025, Before Open (Confirmed).

What is Bioline RX Ltd Sponsored ADR (BLRX) earnings time?

Bioline RX Ltd Sponsored ADR (BLRX) earnings time is at Dec 01, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BLRX EPS forecast?

BLRX EPS forecast for the fiscal quarter 2025 (Q3) is -0.36.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing